ArticleTranslational vision science & technology2026
Reproducibility of VF, OCT, and OCTA in Glaucoma: A Prospective Multi-Visit Study.
Article in Translational vision science & technology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
Purpose: To quantify the reproducibility of visual field (VF), optical coherence tomography (OCT), and OCT angiography (OCTA) metrics in primary open-angle glaucoma (POAG). Methods: Thirty-eight POAG patients completed five visits over three months without treatment changes. VF, OCT, and OCTA were obtained. Eyes were classified as mild (mean deviation [MD] > -6 dB) or moderate-to-advanced (MD ≤ -6 dB). Reproducibility was assessed using 95% tolerance limits (TL), intraclass correlation coefficient (ICC), and coefficient of variation (CoV). Mixed-effects models identified factors associated with variability. Results: Thirty-eight participants (age 67 ± 9 years) included 56 mild (74%) and 20 moderate-to-advanced (26%) eyes. VF metrics demonstrated severity-dependent increases in variability, with MD TL widening from ±2 to ±4 dB, ICC decreasing from 0.95 to 0.75, and CoV increasing from 16% to 26%. OCTA metrics also showed severity-related variability, particularly for peripapillary perfusion density (CoV 5% to 9%), whereas macular OCTA parameters showed smaller changes (CoV 1% to 2%). OCT structural measures remained stable across severity stages (peripapillary retinal nerve fiber layer [pRNFL] and ganglion cell-inner plexiform layer [mGCIPL] CoV ∼2%). Worse MD predicted greater variability in VF and OCTA metrics (all P ≤ 0.046), whereas older age, longer axial length, and false-negative rate were associated with greater MD variability (all P ≤ 0.022). Conclusions: VF and OCTA metrics showed severity-dependent variability, whereas OCT structural measures remained stable across severity stages. These findings support modality- and severity-specific thresholds for glaucoma progression. Translational Relevance: This study helps clinicians better distinguish true glaucoma progression from normal test variability across VF, OCT, and OCTA measurements.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.